• Online Features  This Article  • Full text  • PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (17)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neurology  • Neuromuscular diseases  • Genetic Counseling/ Testing/ Therapy  • Genetic Disorders  • Alert me on articles by topic  Social Bookmarking   What's this?

Expectations and Challenges

Louise R. Rodino-Klapac, PhD; Louis G. Chicoine, MD; Brian K. Kaspar, PhD; Jerry R. Mendell, MD

Arch Neurol. 2007;64(9):1236-1241.

Duchenne muscular dystrophy is a debilitating X-linked disease with limited treatment options. We examined the possibility of moving forward with gene therapy, an approach that demonstrates promise for treating Duchenne muscular dystrophy. Gene therapy is not limited to replacement of defective genes but also includes strategies using surrogate genes with alternative but effective means of improving cellular function or repairing gene mutations. The first viral-mediated gene transfer for any muscle disease was carried out at Columbus Children's Research Institute and Ohio State University for limb girdle muscular dystrophy type 2D, and the first viral-mediated trial of gene transfer for Duchenne muscular dystrophy is under way at the same institutions. These studies, consisting of intramuscular injection of virus into a single muscle, are limited in scope and represent phase 1 clinical trials with safety as the primary end point. These initial clinical studies lay the foundation for future studies, providing important information about dosing, immunogenicity, and viral serotype in humans. This article highlights the challenges and potential pitfalls as the field advances this treatment modality to clinical reality.

Author Affiliations: Center for Gene Therapy, Columbus Children's Research Institute and Columbus Children's Hospital, and the Department of Pediatrics, Ohio State University, Columbus.

CiteULike    Connotea    Delicious    Digg    Facebook    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Evaluation of the therapeutic potential of carbonic anhydrase inhibitors in two animal models of dystrophin deficient muscular dystrophy
Giacomotto et al.
Hum Mol Genet 2009;18:4089-4101.
ABSTRACT | FULL TEXT  

Gene Therapy and Informed Consent Decision Making: Nursing Research Directions
Kaspar et al.
Biol Res Nurs 2009;11:98-107.
ABSTRACT  

Overexpression of Galgt2 in skeletal muscle prevents injury resulting from eccentric contractions in both mdx and wild-type mice
Martin et al.
Am. J. Physiol. Cell Physiol. 2009;296:C476-C488.
ABSTRACT | FULL TEXT  

Gene Therapy in Heart Failure
Vinge et al.
Circ. Res. 2008;102:1458-1470.
ABSTRACT | FULL TEXT